Merck completes acquisition of Austrian vaccine developer Themis Bioscience

TAGS

Pharma giant Merck has wrapped up its previously announced acquisition of Austrian vaccine developer .

The Austrian company is focused on developing and immune-modulation therapies for infectious diseases and cancer.

Merck announced the deal last month in a move to gain access to Themis Bioscience’s vaccine candidate. Read more about Merck acquisition of Themis Bioscience here.

See also  Novartis to expand renal portfolio with Chinook Therapeutics acquisition

The transaction was cleared by the US Federal Trade Commission and prior to that Merck had secured merger control clearance from the Austrian Federal Competition Authority.

Themis is now a fully-owned subsidiary of Merck.

The pharma giant said that it will initially focus on speeding up the development of Themis Bioscience’s measles vector-based vaccine candidate, which is presently in pre-clinical development. Clinical studies of the coronavirus vaccine candidate are targeted to begin later this year.


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

CATEGORIES
TAGS
Share This